BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

(Neutral)

Rhea-AI Summary

BioMarin (Nasdaq: BMRN) entered into binding global settlement terms with Ascendis Pharma A/S, resolving all pending patent-related and ancillary disputes concerning Ascendis's drug Yuviwel, including a Section 337 investigation before the U.S. International Trade Commission and litigation in multiple countries.

Ascendis will pay BioMarin a 20% royalty on net Yuviwel sales in the U.S., retroactive to the first commercial sale, and 18% on net sales in the EU, Brazil and South Korea through May 2030. The settlement includes a license to BioMarin patents related to Yuviwel for all current and potential indications, as well as combination use, and recognizes the value of BioMarin’s CNP technology and VOXZOGO.

Positive

20% U.S. Yuviwel royalty on net sales, retroactive
18% royalty on Yuviwel net sales in EU, Brazil, South Korea
Royalty stream from Yuviwel sales runs until May 2030
Global patent and ancillary disputes with Ascendis fully resolved
ITC Section 337 investigation and multi-country IP litigation dismissed

Negative

Royalty obligations on Yuviwel sales end after May 2030
Future royalty revenue depends on Ascendis achieving Yuviwel sales

Market Context

Current peer data showed ASND down 0.08%, while the momentum scanner identified no peers in momentum...

Analysis

Current peer data showed ASND down 0.08%, while the momentum scanner identified no peers in momentum. The settlement added licensing economics, with value tied to Yuviwel net sales and royalties ending in May 2030.

Key Figures

U.S. royalty: 20% of net sales International royalty: 18% of net sales Royalty end date: May 2030 +2 more

5 metrics

U.S. royalty 20% of net sales Yuviwel sales, retroactive to first commercial sale

International royalty 18% of net sales European Union, Brazil and South Korea until May 2030

Royalty end date May 2030 Royalty terms in specified international markets

First-in-disease medicines six BioMarin development track record

Commercial therapies nine BioMarin company description

Historical Context

5 past events · Latest: Aug 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 18	Therapeutic acquisition	Positive	+0.5%	BioMarin agreed to acquire Alesta and its ALE1 clinical-stage asset.
Aug 10	Conference participation	Neutral	+8.0%	BioMarin announced participation in the Canaccord Genuity Growth Conference.
Aug 06	Second-quarter earnings	Positive	+3.8%	Revenue growth and raised full-year guidance accompanied quarterly results.
Jul 30	Earnings call scheduling	Neutral	-1.3%	BioMarin scheduled its second-quarter financial results conference call and webcast.
Jul 27	Research collaboration	Positive	+1.6%	BioMarin and n-Lorem announced an ASO collaboration for ReNU syndrome.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent BioMarin news reactions were mostly aligned with the event sentiment, with four aligned events and one divergence.

Key Terms

section 337 investigation, c-type natriuretic peptide, hypochondroplasia

3 terms

section 337 investigation regulatory

"dismiss the pending Section 337 investigation before the ITC"

A Section 337 investigation is a U.S. International Trade Commission (ITC) inquiry into whether certain imported goods violate U.S. trade laws, most often by infringing intellectual property or engaging in unfair competition. The ITC can order import bans or other remedies, which can immediately block products from entering U.S. markets; that outcome can materially affect a company’s sales, supply chains, and competitive position, making the probe important to investors.

c-type natriuretic peptide medical

"pioneering innovations in C-type natriuretic peptide (CNP) technology"

C-type natriuretic peptide is a small, naturally occurring protein the body uses to relax blood vessels and regulate cell growth, especially in blood vessel walls and bone. Think of it as a local traffic cop that calms traffic and tells cells when to slow down dividing. For investors, it matters because drugs or tests that mimic or measure this peptide can become treatments or diagnostics for heart, vascular and growth disorders, affecting market value and regulatory risk.

hypochondroplasia medical

"including achondroplasia and hypochondroplasia"

A genetic growth disorder that causes shorter-than-average limbs and reduced adult height by affecting bone development; think of it as a change in the body’s blueprint that slows or limits normal bone lengthening. For investors, hypochondroplasia matters because it defines a clear patient group and medical need that can drive demand for diagnostics, therapies, or supportive services, shaping market size, clinical development paths, and regulatory attention in related biotech and healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/31/2026 - 02:00 AM

Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis

SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea until May 2030.

"This outcome incentivizes companies like BioMarin to keep investing in the kind of long-term innovation that is critical to bringing breakthrough treatments to the people who need them," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "We have spent decades focused on understanding the underlying biology of rare genetic conditions, building the deep scientific expertise that led to our development of six first-in-disease medicines for patients. We look forward to continuing to innovate, bringing forward the next generation of medicines for people with serious genetic conditions, and building on our ongoing momentum for children with achondroplasia."

The scope of the settlement includes a license for BioMarin's patents that relate to Yuviwel for all current and potential indications, including achondroplasia and hypochondroplasia. It also covers the use of Yuviwel in combination with other medicines. Under the terms of the agreement, BioMarin will dismiss the pending Section 337 investigation before the ITC and the parties will resolve all claims relating to the asserted intellectual property, including litigation pending in Brazil, Denmark, Germany, South Korea and the Northern District of California.

Reaching this agreement recognizes the value of BioMarin's pioneering innovations in C-type natriuretic peptide (CNP) technology, including the development of VOXZOGO^® (vosoritide), while providing a framework that enables continued access to medicine for children with achondroplasia around the world.

About BioMarin

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: the settlement and license agreement with Ascendis Pharma A/S, including expected benefits of such agreement and anticipated royalty payments, and future commercialization of licensed products and BioMarin's expectations to continue to innovate, bringing forward the next generation of medicines for people with serious genetic conditions, and building on its momentum for children with achondroplasia. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin's ability to enforce the agreement; actual sales of licensed products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin^® and VOXZOGO^® are registered trademarks of BioMarin Pharmaceutical Inc.

Contacts:

Investors	Media
Traci McCarty	Andrew Villani
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(628) 269-7393

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-announces-global-settlement-with-ascendis-pharma-as-ascendis-will-pay-royalties-to-biomarin-on-yuviwel-sales-in-us-eu-brazil-and-south-korea-302864555.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

What did BioMarin (BMRN) announce about its patent settlement with Ascendis Pharma on August 30, 2026?

BioMarin announced a binding global settlement with Ascendis Pharma resolving all patent-related disputes involving Yuviwel. According to BioMarin, the agreement includes royalty payments on Yuviwel sales and dismissal of proceedings before the U.S. ITC and courts in several countries.

What royalties will BioMarin (BMRN) receive on Yuviwel sales under the Ascendis settlement?

BioMarin will receive a 20% royalty on net Yuviwel sales in the U.S. and 18% in the EU, Brazil, and South Korea. According to BioMarin, the U.S. royalty is retroactive to first commercial sale and all royalties run until May 2030.

How long will the Yuviwel royalty payments to BioMarin (BMRN) from Ascendis last?

The Yuviwel royalty payments to BioMarin are scheduled to run until May 2030. According to BioMarin, the 20% U.S. and 18% EU, Brazil, and South Korea royalties apply to net sales over this period, subject to Yuviwel’s commercial performance.

Which legal disputes between BioMarin (BMRN) and Ascendis are resolved by the Yuviwel settlement?

The settlement resolves all pending patent and ancillary disputes related to Yuviwel, including a Section 337 investigation at the U.S. ITC. According to BioMarin, it also covers litigation in Brazil, Denmark, Germany, South Korea, and the Northern District of California.

What patent rights and indications are covered in the BioMarin–Ascendis Yuviwel license agreement?

The settlement grants Ascendis a license to BioMarin patents related to Yuviwel for all current and potential indications. According to BioMarin, this includes achondroplasia, hypochondroplasia, and use of Yuviwel in combination with other medicines across these indications.

How does the Yuviwel settlement affect BioMarin’s CNP technology and VOXZOGO franchise (BMRN)?

The agreement recognizes the value of BioMarin’s CNP technology and VOXZOGO development. According to BioMarin, it provides a framework that supports continued access to treatment for children with achondroplasia while monetizing its intellectual property through Yuviwel-linked royalties.